SMMT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Summit Therapeutics Inc (SMMT) does not present a strong buy opportunity for a beginner investor with a long-term strategy at this moment. The stock has mixed signals from technical analysis, lacks strong positive catalysts, and faces significant uncertainties in its FDA approval process and competitive positioning in the biotech sector. Considering the investor's impatience and unwillingness to wait for optimal entry points, holding off on this stock is recommended.
The MACD is positive and expanding (0.181), indicating a bullish momentum. RSI is neutral at 66.289, and moving averages are converging, suggesting no clear trend. The stock is trading near its first resistance level (R1: 17.683) in pre-market, with limited upside potential in the short term.
The company has filed for FDA approval for ivonescimab, which is already approved in China. HARMONi-3 squamous cohort data in Q2 could potentially revitalize the stock and lead to FDA engagement.
Jefferies downgraded the stock to Hold with a reduced price target of $15, citing risks in the HARMONi-6 readout and uncertain global translation. Competitive threats from Axsome Therapeutics and Madrigal Pharmaceuticals, which are showing strong revenue growth, further pressure Summit's market position. Lack of statistically significant survival data in Western countries poses a risk to FDA approval.
In 2025/Q4, the company reported no revenue growth (0% YoY) and a net income loss of -$219.17 million, though this was an improvement of 258.11% YoY. EPS improved to -0.29, up 262.50% YoY, but the company remains unprofitable.
Recent analyst ratings are mixed. Jefferies downgraded the stock to Hold with a price target of $15, citing risks in upcoming catalysts. Citi and H.C. Wainwright maintain Buy ratings with price targets of $40 and $30, respectively, but note uncertainties in timelines and data availability. Overall, sentiment is cautious with significant risks highlighted.
